Hims & Hers (HIMS) Jumps 48% Ahead of Earnings

Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks With Monster Returns.

Hims & Hers saw its share prices jump by 48.3 percent week-on-week as investors positioned portfolios ahead of the results of its earnings performance for the first quarter of the year, supported by optimism over its rekindled partnership with Novo Nordisk.

In an updated report, Hims & Hers Health Inc. (NYSE:HIMS) said that it is scheduled to release the results of its earnings performance after market close on May 11, 2026. A conference call will be held to elaborate on the results.

Photo by Suzy Hazelwood on Pexels

For the period, the company expects to grow its year-on-year revenues by 2.4 percent to 6.7 percent to a range of $600 million to $625 million, versus $586 million in the same period a year earlier.

Adjusted EBITDA is projected at a range of $35 million to $55 million, or a decline of 40 percent to 61.6 percent from the $91.1 million in the same comparable period.

Investors are also expected to watch for Hims & Hers Health Inc.’s (NYSE:HIMS) outlook for the second quarter of the year after it renewed its partnership with Novo Nordisk for the sale of the latter’s Wegovy and Ozempic on the HIMS platform. The partnership initially began last year but was terminated a month later after Novo accused Hims of “failing to adhere to the law” by continuing to sell its compounded GLP-1 drugs.

In the newly inked contract, Hims & Hers Health Inc. (NYSE:HIMS) committed to sell only the FDA-approved weight loss drugs, while the compounded GLP-1 versions will be offered only in cases where the needs of the customers cannot be met using the FDA-approved version, and if a provider determines that a compounded product is clinically necessary.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.